Integrative modeling of longitudinal cell-free DNA and tumor volume dynamics: a multimodal quantitative prognostic framework.

Background: Liquid biopsy based on cell-free DNA (cfDNA) in oncology has emerged as a promising technique for tracking cancer dynamics, especially for detecting minimal residual disease. To date, most studies have used cfDNA for static evaluations of tumor burden. In this study, we propose a novel approach integrating serial cfDNA and computed tomography (CT) tumor volume to fully reflect the dynamic nature of tumor response after treatment. Methods: This prospective study involved 25 patients treated with curative-intent radiotherapy for localized non-small cell lung cancer (NSCLC) between June 2019 and November 2020, with 17 subsequently included in final analysis. Longitudinal blood samples were divided into two phases relative to day 3 after treatment initiation, and kinetic parameters, such as velocity and acceleration of cfDNA levels, were calculated. To complement sparse samplings in later days, volume data from routine CT scans were incorporated. K-means clustering using two different variable sets (cfDNA only and cfDNA with volume parameters) and conventional assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 were applied to stratify patients, and their performance was compared. Results: The model incorporating both cfDNA and volume parameters effectively separated responders (mean progression-free survival, 44.2 months) from non-responders [16.6 months, P=0.02; area under the receiver operating characteristic curve (AUC) =0.955], outperforming cfDNA only model (36.0 Conclusions: Therefore, our study demonstrates that integration of longitudinal cfDNA and tumor volume dynamics yielded improved assessment of treatment response and prognosis in NSCLC.